Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese SubjectsWith Type 2 Diabetes A Substudy of the SCOUT Trial

RESEARCH DESIGN AND METHODSdThis analysis included 8,192 overweight patients with type 2 diabetes mellitus from the Sibutramine Cardiovascular Outcomes Trial (SCOUT) randomized to lifestyle intervention with or without sibutramine for up to 6 years. Patients were grouped according to hypoglycemic treatment at baseline. The primary end point was the time from randomization to the first occurrence of a primary outcome event (POE), nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death. Multivariable Cox proportional hazards regression models were used to assess the impact of antiglycemic treatment on POE and all-cause mortality.